



Docket No. 5063 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of) Group Art Unit: 1632
Luz MONTESCLAROS et al.) Examiner: To be assigned
Serial No.: 10/618,493	CERTIFICATE OF MAILING under 37 C.F.R. 1.8
Filed: July 11, 2003	I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:
For: METHODS AND KITS FOR OBTAINING NUCLEIC ACID FROM BIOLOGICAL SAMPLES	March 4, 2005 Date of Deposit Debovah A. He jarro Name of Depositing Party Signature of Depositing Party
Confirmation No.: 5407) Squares a separation of the separation of th

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO/SB/08A) of which they are aware, which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

- (a) [] accompanies a new patent application submitted herewith.
- (b) [] is filed within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491.
- (c) [X] as far as is known to the undersigned, is filed before the mailing date of a first Office action on the merits.
- (d) [] as far as is known to the undersigned, is filed before the mailing date of a first Office action after the filing of a request for continued examination under § 1.114.

- (e) [] is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned, prior to the mailing date of either a final action under §1.113, a notice of allowance under §1.311, whichever occurs first, and is accompanied by either the fee (\$180) set forth in 37 CFR §1.17(p) or a certification as specified in 37 CFR §1.97(e), as checked below. Should any fee be due, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.
- (f) [] is filed after the mailing date of either a final rejection or a notice of allowance, but on or before the payment of the issue fee, and is accompanied by the fee (\$180) set forth in 37 CFR §1.17(i)(1) and a certification as specified in 37 CFR §1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the information disclosure statement. The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 01-2213 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement. Any deficiency or overpayment should be charged or credited to this deposit account. A duplicate of this sheet is enclosed.

[If either of boxes (e) or (f) is checked above, the following "certification" under 37 CFR §1.97(e) may need to be completed.] The undersigned certifies that:

- [] Each item of information contained in the information disclosure statement was first cited in a communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- [] No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this information disclosure statement.

A copy of the non-patent literature and foreign patents listed on PTO/SB/08A are being supplied herewith:

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Date:

Scott R. Bortner, Reg. No. 34,298

Attorney for Applicants

Correspondence Address

Customer Number 22896 APPLERA CORPORATION Applied Biosystems Group 850 Lincoln Centre Drive Foster City, CA 94404 (760) 931-6676 (Phone) (650) 638-6677 (Fax)

P:pase	type.g.ptus	sign (+) inside	this box.
--------	-------------	-----------------	-----------

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0331

pe.c. plus sign (+) inside this box.		PTO/SB/08A (03-0 Approved for use through 10/31/2002. OMB 0651-00 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC	31
Under the Paperwork Reduction Act of 19	98, no persons are required to re-	spond to a collection of information unless it displays a valid OMB control number	25
Substitute for form 1449A/PTO	1446 J. J. 2007	Complete if Known	

MAR 0 0 2005 INFORMATION DESCLOSU STATEMENT BY APPLE

(Use as many sheets as necessary)

Sheet 1	of 2	
---------	------	--

Complete if Known				
Application Number	10/618,493			
Filing Date	July 11, 2003			
First Named Inventor	Luz MONTESCLAROS et al.			
Group Art Unit	1632			
Examiner Name To be assigned				
Attorney Docket No.	5063 US			

					U.S	S. PATENT DOCUMENT	'S		
Examiner	Cite	·	U.S. Patent Document			me of Patentee or Applicant	Date of Publication	Pages, Columns, Lines Where	
Initials*	No.1	Numbe	r	Kind Code ²		of Cited Document	of Cited Document MM-DD-YYYY	Relevant Passages or Relev Figures Appear	
	1		0,172	B1	WEB	ER et al.	04/30/2002		
	2	5,86	3,726		HAR	LEY et al.	01/26/1999		
	3	2002	/0177139	A1	GRE	ENFIELD et al.	11/28/2002		
					-				
					1				
						···			
								•	
								-	
					FORE	IGN PATENT DOCUME	INTE		
Examiner	Cite		Foreign Patent De		TOKE	IGN PATENT DOCUME			
Initials*	No. 1 Office ³		Number ⁴	1	Kind Name of Patente	Name of Patentee or Applicar of Cited Document		Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	76
	4	WO	00/63362			ANNOVIS, INC.	10/26/2000		
	5	WO	03/033739		A1	GENTRA SYSTEMS, INC.	04/24/2003		
	6	WO	03/046146		A2	APPLERA CORPORATION	06/05/2003		
	7	EP	0 268 946		A1	DIAGEN	06/01/1988		
	8	EP	1 201 753		A1	ROCHE DIAGNOSTICS GmbH	04/03/2003 H		
						<u> </u>			
		<u> </u>							
	L	L						<u> </u>	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

•		PTO/SB/08A (08-00
Pluase type of plus sign (+) inside this box.		Approved for use through 10/31/2002. OMB 0651-003
	APE.	U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no response are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known MAR 0 C 2005 Substitute for form 1449A/PTO **Application Number** 10/618,493 INFORMATION DISCLOSURE July 11, 2003 Filing Date **First Named Inventor** Luz MONTESCLAROS et al. STATEMENT BY APPLICANT **Group Art Unit** 1632 **Examiner Name** To be assigned (Use as many sheets as necessary) 2 5063 US Sheet Attorney Docket No. of

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	9	International Search Report mailed 6 December 2004 issued in International Application No. PCT/US2004/022250	
	10	Written Opinion of the International Search Report mailed 6 December 2004 issued in International Application No. PCT/US2004/022250	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.